SSBP

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

Retrieved on: 
Thursday, September 14, 2023
Honey, SSBP, Clinician Administered PTSD Scale, University, MBBS, Medical school, DM, FRACP, Associate professor, Efficacy, Adolescence, Maharashtra University of Health Sciences, University of Queensland, INSPIRE, Syndrome, The Society, Pharmaceutical industry, Vaccine, Cannabidiol

Helen (Honey) Heussler, MBBS FRACP, DM, Associate Professor, Faculty of Medicine, Child Health Research Centre, University of Queensland, Australia, will present data from the open-label Phase 2 INSPIRE trial.

Key Points: 
  • Helen (Honey) Heussler, MBBS FRACP, DM, Associate Professor, Faculty of Medicine, Child Health Research Centre, University of Queensland, Australia, will present data from the open-label Phase 2 INSPIRE trial.
  • A copy of the presentation will be available on the Zynerba corporate website at www.zynerba.com/publications .
  • Zygel was shown to be generally well tolerated, and the safety profile was consistent with previously released data from other Zygel clinical trials.
  • Three patients reported treatment related adverse events which were all mild in severity and application site related.

OTC Markets Group Welcomes SSB Bancorp Inc. to OTCQX

Retrieved on: 
Monday, May 1, 2023
OTCQX, KBW, CFO, SSBP, Societe Generale Ghana, Security (finance)

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced SSB Bancorp Inc. (OTCQX: SSBP), the holding company for SSB Bank, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced SSB Bancorp Inc. (OTCQX: SSBP), the holding company for SSB Bank, has qualified to trade on the OTCQX® Best Market.
  • SSB Bancorp Inc. upgraded to OTCQX from the Pink® market.
  • SSB Bancorp Inc. began trading on OTCQX under the symbol “SSBP.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • Graduating to the OTCQX Market marks an important milestone for community banks in the U.S. public markets.

Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

Retrieved on: 
Monday, November 14, 2022
Marketing, Anxiety, Autism, Behavior, Patent, Security (finance), Form 10-K, Press release, Growth, INSPIRE, ASD, Royal commission, NDA, LPC, Bill, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infection, Clinical Global Impression, Fragile X syndrome, SSBP, COVID-19, The Society, Poster, NORD, FDA, Fast Track, European Commission, Degenerative disease, National Organization for Rare Disorders, FXS, Depression, Annual report, Canaccord Genuity, Food, Skin, Microdeletion syndrome, DiGeorge syndrome, Research, Fragile, Patient, Pharmaceutical industry, Jean-François Zygel, Cannabidiol

DEVON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2022, and provided an overview of recent operational highlights and a pipeline update.

Key Points: 
  • $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into first quarter 2024
    DEVON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2022, and provided an overview of recent operational highlights and a pipeline update.
  • The Company currently plans to initiate a Phase 3 program in children and adolescents with 22q following topline results from RECONNECT.
  • Research and development expenses were $5.0 million for the third quarter of 2022, including stock-based compensation of $0.5 million.
  • General and administrative expenses were $3.5 million in the third quarter of 2022, including stock-based compensation expense of $0.6 million.

Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

Retrieved on: 
Wednesday, August 31, 2022
European Medicines Agency, Infection, COVID-19, Security (finance), Form 10-K, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SSBP, DiGeorge syndrome, Fragile X syndrome, Food, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, GLOBE, Nasdaq, Company, Twitter, The Society, Annual report, Growth, Autism, Marketing, Patient, Pharmaceutical industry

DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022.

Key Points: 
  • DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022.
  • A copy of the presentation slides will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/ .
  • Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders.
  • Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release.

SSB Bancorp, Inc Reports Financial Results For the Year Ended December 31, 2021

Retrieved on: 
Wednesday, April 13, 2022
News, Federation, OTC, Year, SSBP, Company, Bank, Societe Generale Ghana, Forward-looking statement, Audit

PITTSBURGH, April 13, 2022 /PRNewswire/ -- SSB Bancorp, Inc (OTC: SSBP news) (the "Company"), the holding company for SSB Bank (the "Bank"), today announced the Company's consolidated results of operations for the year ended December 31, 2021.

Key Points: 
  • PITTSBURGH, April 13, 2022 /PRNewswire/ -- SSB Bancorp, Inc (OTC: SSBP news) (the "Company"), the holding company for SSB Bank (the "Bank"), today announced the Company's consolidated results of operations for the year ended December 31, 2021.
  • Net earnings for the year ended December 31, 2021, were impacted by a decrease in gain on sales of loans of $1.1 million due to compressed margins when compared with the prior year.
  • Also, noninterest expense was higher in 2021 due to an increase in salaries and employee benefits of $689,000 when comparing the year ended December 31, 2021, with the prior year.
  • Total assets increased by $975,000 to $234.9 million at December 31, 2021, compared to $234.0 million at December 31, 2020.